Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Quantum BioPharma Ltd
QNTM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.51
0.07
4.86%
Ult. Agg.: Nov 17, 10:11 AM
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data gio nov 12th, prima dell'apertura del mercato
Quantum BioPharma Financials
Quantum BioPharma (QNTM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings
Thermo Fisher reports Q3 earnings Oct. 21, with analysts expecting $6.40 EPS and $11.93B revenue; analysts remain bullish, raising price targets.
Avi Kapoor
PRO
Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.93) by 23.66 percent. This is a 65.53 percent increase over losses of $(2.06) per share from
Benzinga Newsdesk
PRO
Quantum BioPharma Q3 EPS $(1.25) Misses $(0.08) Estimate
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(0.08) by 1462.5 percent. This is a 71.4 percent increase over losses of $(4.37) per share
Benzinga Newsdesk
PRO
Quantum BioPharma Q2 EPS $(3.23) Compared With $(0.08) YoY
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(3.23) per share which missed the analyst consensus estimate of $(0.07) by 4514.29 percent. This is a 3937.5 percent decrease over losses of $(0.08) per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2025
Benzinga Insights
Dow Edges Higher; US Weekly Jobless Claims Increase
Avi Kapoor